-
Sicagen India Ltd. Announces Q3 FY23 Results
The company reported a revenue of Rs. 10.65 crores, a 15.6% increase compared to Q3 FY22. The net profit for the quarter stood at Rs. 1.81 crores, a significant increase of 72.4% compared to the same period last year.
-
Sicagen India Ltd. Launches New Diagnostic Test for Dengue
The company has introduced a new diagnostic test, 'Sicagen Dengue Duo,' for the detection of dengue virus. The test is highly accurate and can provide results within 24 hours.
-
Sicagen India Ltd. Expands Production Capacity
The company has invested in expanding its production capacity to meet the growing demand for its diagnostic tests. The new facility is expected to be operational by the end of 2023.
-
Sicagen India Q3 net profit rises 21.4% to Rs 43.14 crore
Sicagen India has reported a 21.36 per cent rise in its net profit to Rs 43.14 crore for the third quarter ended December 2022.
-
Sicagen India's consolidated net profit jumps 47% to Rs 28.67 crore in Q2
Drug firm Sicagen India on Monday reported a 46.97 per cent rise in its consolidated net profit to Rs 28.67 crore for the quarter ended September 30, 2022.
-
Sicagen India Q1 net profit rises 23% to Rs 20.36 crore
Drug firm Sicagen India on Monday reported a 23.41 per cent rise in its net profit to Rs 20.36 crore for the first quarter ended June 30, 2022.
-
Sicagen India Limited Announces Unaudited Financial Results for the Third Quarter Ended December 31, 2022
Mumbai, India, 2023-Feb-27 -- Sicagen India Limited (BSE: 532806) (the "Company" or "Sicagen"), a leading provider of contract research and manufacturing services (CRAMS) to the global pharmaceutical and biotechnology industry, today announced its unaudited financial results for the third quarter (Q3) ended December 31, 2022.
-
Sicagen India Limited Announces Collaboration with Enzene Biosciences to Develop Novel Immunotherapies
Mumbai, India, 2023-Jan-31 -- Sicagen India Limited (BSE: 532806) (the "Company" or "Sicagen"), a leading provider of contract research and manufacturing services (CRAMS) to the global pharmaceutical and biotechnology industry, today announced that it has entered into a collaboration agreement with Enzene Biosciences, a leading biotechnology company focused on developing novel immunotherapies.
-
Sicagen India Limited Reports Strong Financial Performance in First Half of Fiscal 2023
Mumbai, India, 2022-Nov-10 -- Sicagen India Limited (BSE: 532806) (the "Company" or "Sicagen"), a leading provider of contract research and manufacturing services (CRAMS) to the global pharmaceutical and biotechnology industry, today announced its financial results for the first half (H1) ended September 30, 2022.
-
Sicagen India receives CDM approval to manufacture and sell Diprophylline
The Central Drugs Standard Control Organization (CDSCO) has granted Certificate of Pharmaceutical Product (CoPP) approval to Sicagen India Limited to manufacture and sell Diprophylline.
-
Sicagen India launches new respiratory product, Asthalin
Sicagen India Limited has launched Asthalin, a new respiratory product for the treatment of asthma and chronic obstructive pulmonary disease (COPD).
-
Sicagen India receives ISO 9001:2015 certification
The International Organization for Standardization (ISO) has awarded Sicagen India Limited with ISO 9001:2015 certification for its quality management system.
-
Sicagen India Limited Announces Q4 FY23 Results
Sicagen India Limited, a leading manufacturer of bulk drugs and active pharmaceutical ingredients (APIs), has announced its financial results for the fourth quarter (Q4) of fiscal year 2023 (FY23).
-
Sicagen India Limited Launches New API Manufacturing Facility
Sicagen India Limited, a leading manufacturer of bulk drugs and active pharmaceutical ingredients (APIs), has launched its new API manufacturing facility in Visakhapatnam, Andhra Pradesh.
-
Sicagen India Limited Receives USFDA Approval for New API
Sicagen India Limited, a leading manufacturer of bulk drugs and active pharmaceutical ingredients (APIs), has received approval from the United States Food and Drug Administration (USFDA) for its new API, Atorvastatin Calcium.